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Introduction
Macrophage activation syndrome (MAS) – is a severe life-
threatening hematological condition, mostly complicated
systemic juvenile idiopathic arthritis (SJIA). Early detection
of MAS can lead to appropriate therapeutic interventions
and change the outcomes. There are no strict criteria for
early MAS detection in SJIA. Currently applied HLH
criteria can determinate only advanced stage of MAS,
which lead to delay diagnosis, late start of specific
treatment and associated with poor outcomes. There are
several sets of preliminary criteria of MAS in SJIA.
Objectives
The purpose of our study was to detect early clinical and
laboratorial signs able to discriminate macrophage activa-
tion syndrome (MAS) from active systemic juvenile idio-
pathic arthritis (SJIA) without MAS.
Methods
Our retrospective study was based on reviewing the medi-
cal charts of the children, admitted to the rheumatology
department with active SJIA and definite MAS (n=18) and
without MAS (n=40). We evaluated the data related to
SJIA and MAS at the moment of the patient’s admission.
If the patient had signs of MAS since admission or devel-
oped definite MAS later during this flare he was referred
to the main group. The children, who did not have MAS
during the flare episode and did not have MAS in the past
medical history, were in the control group. We calculated
the cut-off points for MAS parameters, performed the
analysis of sensitivity and specificity, identified the predic-
tors and provided the preliminary diagnostic rule through
“the number of criteria present” approach.
Results
The clinical signs were relevant to MAS in SJIA: oli-
goarthicular disease course (OR=5.6), splenomegaly
(OR=67.6), hemorrages (OR=33.0), respiratory failure
(OR=11.3). The involvement of wrist (OR=0.2), MCP
(OR=0.1) and PIP joints (OR=0.1) were protective against
MAS development. The best cut-offs for laboratorial para-
meters were PLT≤211*109/l, WBC≤9.9*109/l, AST>59.7
U/l, LDH>882 U/l, albumin≤2.9 g/dl, ferritin>400 μg/l,
fibrinogen≤1.8 g/l, proteinuria. The laboratorial variables
were more precise in the discrimination of early MAS
than clinical: any 3 or more laboratorial criteria provided
the highest specificity (1.0) and sensitivity (1.0) and
OR – 2997.
Conclusion
We detected clinical and laboratorial markers and created
preliminary diagnostic (laboratorial) guidelines for early
discrimination of MAS in active SJIA.
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